Global industries and economies continue on their wild ride, sparked from the pandemic, which thrusted biotechnology center stage during the development of vaccines and therapies. However, sentiment has cooled, driven by a convergence of complex factors, making identifying the next wave of emerging risks and opportunities an acute challenge. Armed with world class pharmaceutical industry, company, drug development, and financial data, Bloomberg Intelligence analysts join Demy-Colton to discuss the data-driven outlook for the biotech sector, for the balance of the year.
